Shares in Arcus and Gilead have been hit by a negative market reaction to their latest Phase II data update on domvanalimab, a TIGIT cancer immunotherapy candidate being studied in first-line non-small cell lung cancer (NSCLC).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?